EANS-News: Balda AG Balda shareholders approve dividend payment of EUR 2.00
per share
--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Annual & Special Corporate Meetings
Subtitle: - Ted Gerlach elected as new member of the supervisory board
- Plastic specialist is in advanced negotiations regarding an acquisition in the
Medical division
Bielefeld (euro adhoc) - Bielefeld, 7th November 2012 - This Wednesday the
annual general meeting of Balda AG, Bad Oeynhausen, approved a dividend payment
of EUR 2.00 per share for the short financial year 2012 (1st January to 30th
June 2012). As such a total of around EUR 117.8 million will be distributed. The
shareholders have therefore once again participated in the proceeds arising from
the sale of the majority of the shares in the touchscreen manufacturer TPK
Holding during the short financial year. With a presence of 60.1% of the total
share capital, the shareholders approved the proposed dividend with a
substantial majority.
Additionally, the annual general meeting elected Mr Ted Gerlach as a new
supervisory board member and successor to Mr Chun-Chen Chen in this role. Mr
Gerlach is the Managing Director of BluePoint Controls Inc. with its head office
in Milpitas, California, USA. He will bring with him his comprehensive knowledge
of the North American market, which is of growing significance to the further
development of the Balda Group. The annual general meeting also confirmed the
posts of the supervisory board members Dr. Michael Naschke and Mr Yu-Sheng Kai.
The board elected Dr. Naschke as supervisory board chairman and Mr Gerlach as
his deputy during its constituent session.
Chief Executive Officer Dominik Müser reported to the annual general meeting on
the progress of the Balda Group's reorientation during the year 2012,
principally encompassing a Buy and Build strategy for the Balda Medical segment.
The unaltered objective remains to increase the Group's revenues in the next
three years to EUR 150 to 200 million, and in doing so to increase the Medical
segment revenues to a figure considerably in excess of EUR 100 million. At the
present time Balda is in advanced negotiations regarding the acquisition of
companies in North America and Western Europe.
Dominik Müser, Chief Executive Officer of Balda AG: "We are very confident about
the future of Balda. At the beginning of this year we found ourselves faced with
many pressing tasks, the greatest part of which we have already taking care of.
This includes the implementation of a growth strategy for Balda Medical, the
restructuring of the Electronic Products segment and the sale of the majority of
the TPK shares. Balda now has every chance of developing into a growing,
profitable midcap, one that is valued on the stock market."
Note to the editors:
The statements made by Chief Executive Officer of Balda AG Dominik Müser at the
annual general meeting can be found on the Balda AG website (www.balda.de).
Further inquiry note:
Frank Elsner
Frank Elsner Kommunikation für Unternehmen GmbH
Tel.: +49 - 54 04 - 91 92 0
Fax: +49 - 54 04 - 91 92 29
Mail:{office@elsner-kommunikation.de}[HYPERLINK:
mailto:office@elsner-kommunikation.de]
end of announcement euro adhoc
--------------------------------------------------------------------------------
company: Balda AG
Bergkirchener Str. 228
D-32549 Bad Oeynhausen
phone: +49 (0) 5734 9 22-0
FAX: +49 (0) 5734 922-2747
mail: info@balda.de
WWW: http://www.balda.de
sector: Semiconductors & active components
ISIN: DE0005215107
indexes: CDAX, Prime All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English